United States Biotechnology & Medical Research

Flexion Therapeutics Inc (FLXN)

Track

Track

Ticker: FLXN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Muzikant Adam Chief Business Officer Officer
Transaction date
Sale
Price
384.45
Quantity 64,150 -43.2%
Value US$357,714
1.4
Arkowitz David Chief Financial Officer Officer
Transaction date
Sale
Price
209.61
Quantity 95,959 +16.6%
Value US$2,085,830
Layman Melissa Chief Commercial Officer Officer
Transaction date
Sale
Price
411.21
Quantity 77,955 +43.7%
Value US$2,710,661
Layman Melissa Chief Commercial Officer Officer
Transaction date
Sale
Price
12.55
Quantity 2,624 -2.9%
Value US$32,931
KELLEY SCOTT Chief Medical Officer Officer
Transaction date
Planned sale
Price
11.13
Quantity 6,829 -5.7%
Value US$76,007
3.4
Wentworth Kerry Chief Regulatory Officer Officer
Transaction date
Planned sale
Price
11.13
Quantity 6,829 -5.7%
Value US$76,007
1.4
Arkowitz David Chief Financial Officer Officer
Transaction date
Sale
Price
11.13
Quantity 6,073 -3.9%
Value US$67,592
Muzikant Adam Chief Business Officer Officer
Transaction date
Sale
Price
11.13
Quantity 4,005 -5.2%
Value US$44,576
2.9
Levine Mark S. General Counsel Officer
Transaction date
Sale
Price
11.13
Quantity 6,829 -6.0%
Value US$76,007
Willwerth Christina Chief Strategy Officer Officer
Transaction date
Sale
Price
11.13
Quantity 6,602 -5.4%
Value US$73,480
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
9.75
Quantity 10,256 +3.0%
Value US$99,996
3.2
Stejbach Mark Non-Executive Director
Transaction date
Purchase
Price
9.75
Quantity 2,051 +inf%
Value US$19,997
1.4
Arkowitz David Chief Financial Officer Officer
Transaction date
Planned sale
Price
10.88
Quantity 2,413 -2.0%
Value US$26,253
KELLEY SCOTT Chief Medical Officer
Transaction date
Sale
Price
0.00
Quantity 3,724
Value US$0
2.9
Levine Mark S. General Counsel
Transaction date
Planned sale
Price
0.00
Quantity 3,724
Value US$0
1.4
Arkowitz David Chief Financial Officer
Transaction date
Sale
Price
0.00
Quantity 3,095
Value US$0
3.4
Wentworth Kerry Chief Regulatory Officer
Transaction date
Planned sale
Price
0.00
Quantity 3,724
Value US$0
Bodick Neil Chief Scientific Officer
Transaction date
Sale
Price
0.00
Quantity 3,851
Value US$0
Willwerth Christina Chief Strategy Officer
Transaction date
Sale
Price
0.00
Quantity 3,533
Value US$0
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
10.74
Quantity 2,000 +4.6%
Value US$21,480
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
10.85
Quantity 2,317 +3.3%
Value US$25,136
1.4
Arkowitz David Chief Financial Officer
Transaction date
Purchase
Price
11.05
Quantity 2,500 +2.9%
Value US$27,627
2.6
MERRIFIELD C ANN Non-Executive Director
Transaction date
Purchase
Price
12.64
Quantity 8,000 +400.0%
Value US$101,120
1.4
Arkowitz David Chief Financial Officer Officer
Transaction date
Purchase
Price
11.99
Quantity 4,000 +4.8%
Value US$47,960
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
12.48
Quantity 4,012 +5.7%
Value US$50,067
1.4
Arkowitz David Chief Financial Officer Officer
Transaction date
Planned sale
Price
10.06
Quantity 2,248 -2.6%
Value US$22,615
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
12.36
Quantity 4,046 +6.1%
Value US$50,009
Bodick Neil Chief Scientific Officer Officer
Transaction date
Planned sale
Price
12.36
Quantity 746 -1.1%
Value US$9,221
Clayman Michael D. President and CEO Executive Director
Transaction date
Planned sale
Price
12.36
Quantity 3,278 -4.7%
Value US$40,516
2.9
Levine Mark S. General Counsel Officer
Transaction date
Planned sale
Price
12.36
Quantity 734 -7.5%
Value US$9,072
3.4
Wentworth Kerry Chief Regulatory Officer Officer
Transaction date
Planned sale
Price
12.36
Quantity 622 -5.3%
Value US$7,688
KELLEY SCOTT Chief Medical Officer Officer
Transaction date
Planned sale
Price
12.36
Quantity 622 -3.9%
Value US$7,688
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
17.10
Quantity 5,000 +7.8%
Value US$85,476
Arkowitz David Chief Financial Officer Officer
Transaction date
Purchase
Price
16.56
Quantity 4,000 +9.0%
Value US$66,222
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
22.33
Quantity 10,000 +15.3%
Value US$223,300
Arkowitz David Chief Financial Officer Officer
Transaction date
Purchase
Price
23.42
Quantity 4,000 +9.9%
Value US$93,680
Bodick Neil Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.00
Quantity 16,492 -20.9%
Value US$412,300
Bodick Neil Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.10
Quantity 33,508 -29.8%
Value US$841,192
Bodick Neil Chief Scientific Officer
Transaction date
Purchase
Price
24.66
Quantity 1,000 +inf%
Value US$24,656
Bodick Neil Chief Scientific Officer
Transaction date
Purchase
Price
24.39
Quantity 1,700 +2.7%
Value US$41,457
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
23.60
Quantity 5,000 +16.5%
Value US$118,000
Deniz Yamo Chief Medical Officer
Transaction date
Purchase
Price
24.20
Quantity 1,000 +12.5%
Value US$24,200
Deniz Yamo Chief Medical Officer
Transaction date
Purchase
Price
23.95
Quantity 2,000 +33.3%
Value US$47,900
Deniz Yamo Chief Medical Officer
Transaction date
Purchase
Price
24.55
Quantity 1,000 +20.0%
Value US$24,550
Deniz Yamo Chief Medical Officer
Transaction date
Purchase
Price
25.40
Quantity 1,375 +37.9%
Value US$34,925
Stejbach Mark
Transaction date
Purchase
Price
17.02
Quantity 1,580 +inf%
Value US$26,888
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
17.23
Quantity 5,000 +33.0%
Value US$86,152
COLELLA SAMUEL D Large shareholder
Transaction date
Purchase
Price
17.01
Quantity 5,000 +inf%
Value US$85,048
Bodick Neil Chief Medical Officer Officer
Transaction date
Planned sale
Price
19.39
Quantity 1,700 -4.2%
Value US$32,967
Bodick Neil Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.81
Quantity 5,130 -11.2%
Value US$96,481
Bodick Neil Chief Medical Officer
Transaction date
Planned sale
Price
28.86
Quantity 200 -0.4%
Value US$5,772
Bodick Neil Chief Medical Officer
Transaction date
Planned sale
Price
28.20
Quantity 4,800 -9.4%
Value US$135,360
DRISCOLL FREDERICK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
23.00
Quantity 3,000 -27.8%
Value US$69,000
Bodick Neil Chief Medical Officer
Transaction date
Planned sale
Price
20.41
Quantity 5,000 -8.9%
Value US$102,038
DRISCOLL FREDERICK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
20.42
Quantity 600 -7.2%
Value US$12,250
DRISCOLL FREDERICK W Chief Financial Officer Officer
Transaction date
Planned sale
Price
19.96
Quantity 32,834 -79.7%
Value US$655,429
Bodick Neil Chief Medical Officer
Transaction date
Planned sale
Price
19.15
Quantity 5,000 -8.2%
Value US$95,758
Bodick Neil Chief Medical Officer
Transaction date
Planned sale
Price
18.35
Quantity 5,000 -7.6%
Value US$91,747
Bodick Neil Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.46
Quantity 10,000 -13.2%
Value US$184,628
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
16.38
Quantity 10,000 +30.0%
Value US$163,807
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
18.41
Quantity 1,667 +5.7%
Value US$30,688
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
17.95
Quantity 1,666 +6.1%
Value US$29,900
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 33,333 +inf%
Value US$599,994
Clayman Michael D. President and CEO Executive Director
Transaction date
Purchase
Price
17.90
Quantity 1,666 +6.5%
Value US$29,827
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.71
Quantity 400 +1.6%
Value US$5,483
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.65
Quantity 504 +2.0%
Value US$6,881
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.76
Quantity 4,600 +23.0%
Value US$63,288
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.62
Quantity 13,222 +195.1%
Value US$180,114
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.70
Quantity 3,343 +97.3%
Value US$45,813
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.98
Quantity 3,435 +inf%
Value US$48,020
MERRIFIELD C ANN Non-Executive Director
Transaction date
Purchase
Price
13.39
Quantity 1,000 +100.0%
Value US$13,387
LUBASH BARBARA N Large shareholder
Transaction date
Purchase
Price
14.00
Quantity 4,194 +25.3%
Value US$58,716
COLELLA SAMUEL D Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.00
Quantity 4,194 +25.3%
Value US$58,716
Versant Ventures III, LLC Large shareholder
Transaction date
Purchase
Price
14.00
Quantity 4,194 +25.3%
Value US$58,716
LUBASH BARBARA N Large shareholder
Transaction date
Purchase
Price
14.00
Quantity 710,091 +25.3%
Value US$9,941,274
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-07-20 2021-07-19 S Sale
Muzikant Adam

Chief Business Officer

Officer
64,150 -43.2%
384.45
US$357,714 		64,150 -43.2% 384.45 US$357,714
2021-05-12 2021-05-10 S Sale
1.4
Arkowitz David

Chief Financial Officer

Officer
95,959 +16.6%
209.61
US$2,085,830 		95,959 +16.6% 209.61 US$2,085,830
2021-03-16 2021-03-15 S Sale
Layman Melissa

Chief Commercial Officer

Officer
77,955 +43.7%
411.21
US$2,710,661 		77,955 +43.7% 411.21 US$2,710,661
2021-01-29 2021-01-28 S Sale
Layman Melissa

Chief Commercial Officer

Officer
2,624 -2.9%
12.55
US$32,931 		2,624 -2.9% 12.55 US$32,931
2021-01-07 2021-01-05 PlS Planned sale
KELLEY SCOTT

Chief Medical Officer

Officer
6,829 -5.7%
11.13
US$76,007 		6,829 -5.7% 11.13 US$76,007
2021-01-07 2021-01-05 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer

Officer
6,829 -5.7%
11.13
US$76,007 		6,829 -5.7% 11.13 US$76,007
2021-01-07 2021-01-05 S Sale
1.4
Arkowitz David

Chief Financial Officer

Officer
6,073 -3.9%
11.13
US$67,592 		6,073 -3.9% 11.13 US$67,592
2021-01-07 2021-01-05 S Sale
Muzikant Adam

Chief Business Officer

Officer
4,005 -5.2%
11.13
US$44,576 		4,005 -5.2% 11.13 US$44,576
2021-01-07 2021-01-05 S Sale
2.9
Levine Mark S.

General Counsel

Officer
6,829 -6.0%
11.13
US$76,007 		6,829 -6.0% 11.13 US$76,007
2021-01-07 2021-01-05 S Sale
Willwerth Christina

Chief Strategy Officer

Officer
6,602 -5.4%
11.13
US$73,480 		6,602 -5.4% 11.13 US$73,480
2020-05-27 2020-05-26 B Purchase
Clayman Michael D.

President and CEO

Executive Director
10,256 +3.0%
9.75
US$99,996 		10,256 +3.0% 9.75 US$99,996
2020-05-27 2020-05-26 B Purchase
3.2
Stejbach Mark
Non-Executive Director
2,051 +inf%
9.75
US$19,997 		2,051 +inf% 9.75 US$19,997
2020-05-11 2020-05-07 PlS Planned sale
1.4
Arkowitz David

Chief Financial Officer

Officer
2,413 -2.0%
10.88
US$26,253 		2,413 -2.0% 10.88 US$26,253
2020-01-07 2020-01-03 S Sale
KELLEY SCOTT

Chief Medical Officer
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 PlS Planned sale
2.9
Levine Mark S.

General Counsel
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 S Sale
1.4
Arkowitz David

Chief Financial Officer
3,095
0.00
US$0 		3,095 0.00 US$0
2020-01-07 2020-01-03 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer
3,724
0.00
US$0 		3,724 0.00 US$0
2020-01-07 2020-01-03 S Sale
Bodick Neil

Chief Scientific Officer
3,851
0.00
US$0 		3,851 0.00 US$0
2020-01-07 2020-01-03 S Sale
Willwerth Christina

Chief Strategy Officer
3,533
0.00
US$0 		3,533 0.00 US$0
2019-08-09 2019-08-08 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
2,000 +4.6%
10.74
US$21,480 		2,000 +4.6% 10.74 US$21,480
2019-08-08 2019-08-08 B Purchase Clayman Michael D.

President and CEO

Executive Director
2,317 +3.3%
10.85
US$25,136 		2,317 +3.3% 10.85 US$25,136
2019-06-03 2019-05-31 B Purchase
1.4
Arkowitz David

Chief Financial Officer
2,500 +2.9%
11.05
US$27,627 		2,500 +2.9% 11.05 US$27,627
2019-05-24 2019-05-23 B Purchase
2.6
MERRIFIELD C ANN
Non-Executive Director
8,000 +400.0%
12.64
US$101,120 		8,000 +400.0% 12.64 US$101,120
2019-05-15 2019-05-13 B Purchase
1.4
Arkowitz David

Chief Financial Officer

Officer
4,000 +4.8%
11.99
US$47,960 		4,000 +4.8% 11.99 US$47,960
2019-05-13 2019-05-10 B Purchase
Clayman Michael D.

President and CEO

Executive Director
4,012 +5.7%
12.48
US$50,067 		4,012 +5.7% 12.48 US$50,067
2019-05-09 2019-05-08 PlS Planned sale
1.4
Arkowitz David

Chief Financial Officer

Officer
2,248 -2.6%
10.06
US$22,615 		2,248 -2.6% 10.06 US$22,615
2019-03-13 2019-03-12 B Purchase
Clayman Michael D.

President and CEO

Executive Director
4,046 +6.1%
12.36
US$50,009 		4,046 +6.1% 12.36 US$50,009
2019-01-04 2019-01-03 PlS Planned sale
Bodick Neil

Chief Scientific Officer

Officer
746 -1.1%
12.36
US$9,221 		746 -1.1% 12.36 US$9,221
2019-01-04 2019-01-03 PlS Planned sale
Clayman Michael D.

President and CEO

Executive Director
3,278 -4.7%
12.36
US$40,516 		3,278 -4.7% 12.36 US$40,516
2019-01-04 2019-01-03 PlS Planned sale
2.9
Levine Mark S.

General Counsel

Officer
734 -7.5%
12.36
US$9,072 		734 -7.5% 12.36 US$9,072
2019-01-04 2019-01-03 PlS Planned sale
3.4
Wentworth Kerry

Chief Regulatory Officer

Officer
622 -5.3%
12.36
US$7,688 		622 -5.3% 12.36 US$7,688
2019-01-04 2019-01-03 PlS Planned sale
KELLEY SCOTT

Chief Medical Officer

Officer
622 -3.9%
12.36
US$7,688 		622 -3.9% 12.36 US$7,688
2018-11-13 2018-11-09 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +7.8%
17.10
US$85,476 		5,000 +7.8% 17.10 US$85,476
2018-11-13 2018-11-09 B Purchase Arkowitz David

Chief Financial Officer

Officer
4,000 +9.0%
16.56
US$66,222 		4,000 +9.0% 16.56 US$66,222
2018-08-10 2018-08-09 B Purchase Clayman Michael D.

President and CEO

Executive Director
10,000 +15.3%
22.33
US$223,300 		10,000 +15.3% 22.33 US$223,300
2018-08-10 2018-08-09 B Purchase Arkowitz David

Chief Financial Officer

Officer
4,000 +9.9%
23.42
US$93,680 		4,000 +9.9% 23.42 US$93,680
2018-07-03 2018-07-03 PlS Planned sale Bodick Neil

Chief Scientific Officer

Officer
16,492 -20.9%
25.00
US$412,300 		16,492 -20.9% 25.00 US$412,300
2018-07-03 2018-07-02 PlS Planned sale Bodick Neil

Chief Scientific Officer

Officer
33,508 -29.8%
25.10
US$841,192 		33,508 -29.8% 25.10 US$841,192
2017-11-22 2017-11-21 B Purchase Bodick Neil

Chief Scientific Officer
1,000 +inf%
24.66
US$24,656 		1,000 +inf% 24.66 US$24,656
2017-11-22 2017-11-21 B Purchase Bodick Neil

Chief Scientific Officer
1,700 +2.7%
24.39
US$41,457 		1,700 +2.7% 24.39 US$41,457
2017-11-09 2017-11-08 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +16.5%
23.60
US$118,000 		5,000 +16.5% 23.60 US$118,000
2017-09-15 2017-09-05 B Purchase Deniz Yamo

Chief Medical Officer
1,000 +12.5%
24.20
US$24,200 		1,000 +12.5% 24.20 US$24,200
2017-09-15 2017-09-01 B Purchase Deniz Yamo

Chief Medical Officer
2,000 +33.3%
23.95
US$47,900 		2,000 +33.3% 23.95 US$47,900
2017-09-15 2017-09-01 B Purchase Deniz Yamo

Chief Medical Officer
1,000 +20.0%
24.55
US$24,550 		1,000 +20.0% 24.55 US$24,550
2017-09-15 2017-08-31 B Purchase Deniz Yamo

Chief Medical Officer
1,375 +37.9%
25.40
US$34,925 		1,375 +37.9% 25.40 US$34,925
2017-06-20 2017-06-16 B Purchase Stejbach Mark
1,580 +inf%
17.02
US$26,888 		1,580 +inf% 17.02 US$26,888
2017-06-06 2017-06-05 B Purchase Clayman Michael D.

President and CEO

Executive Director
5,000 +33.0%
17.23
US$86,152 		5,000 +33.0% 17.23 US$86,152
2017-06-06 2017-06-05 B Purchase COLELLA SAMUEL D Large shareholder
5,000 +inf%
17.01
US$85,048 		5,000 +inf% 17.01 US$85,048
2017-05-17 2017-05-15 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
1,700 -4.2%
19.39
US$32,967 		1,700 -4.2% 19.39 US$32,967
2017-05-17 2017-05-15 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
5,130 -11.2%
18.81
US$96,481 		5,130 -11.2% 18.81 US$96,481
2017-04-18 2017-04-17 PlS Planned sale Bodick Neil

Chief Medical Officer
200 -0.4%
28.86
US$5,772 		200 -0.4% 28.86 US$5,772
2017-04-18 2017-04-17 PlS Planned sale Bodick Neil

Chief Medical Officer
4,800 -9.4%
28.20
US$135,360 		4,800 -9.4% 28.20 US$135,360
2017-03-24 2017-03-23 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
3,000 -27.8%
23.00
US$69,000 		3,000 -27.8% 23.00 US$69,000
2017-03-20 2017-03-17 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -8.9%
20.41
US$102,038 		5,000 -8.9% 20.41 US$102,038
2017-03-02 2017-02-28 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
600 -7.2%
20.42
US$12,250 		600 -7.2% 20.42 US$12,250
2017-03-02 2017-02-28 PlS Planned sale DRISCOLL FREDERICK W

Chief Financial Officer

Officer
32,834 -79.7%
19.96
US$655,429 		32,834 -79.7% 19.96 US$655,429
2017-02-27 2017-02-24 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -8.2%
19.15
US$95,758 		5,000 -8.2% 19.15 US$95,758
2017-01-23 2017-01-20 PlS Planned sale Bodick Neil

Chief Medical Officer
5,000 -7.6%
18.35
US$91,747 		5,000 -7.6% 18.35 US$91,747
2016-12-22 2016-12-21 PlS Planned sale Bodick Neil

Chief Medical Officer

Officer
10,000 -13.2%
18.46
US$184,628 		10,000 -13.2% 18.46 US$184,628
2016-12-05 2016-12-01 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
10,000 +30.0%
16.38
US$163,807 		10,000 +30.0% 16.38 US$163,807
2016-11-23 2016-11-23 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,667 +5.7%
18.41
US$30,688 		1,667 +5.7% 18.41 US$30,688
2016-11-23 2016-11-22 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,666 +6.1%
17.95
US$29,900 		1,666 +6.1% 17.95 US$29,900
2016-11-22 2016-11-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
33,333 +inf%
18.00
US$599,994 		33,333 +inf% 18.00 US$599,994
2016-11-22 2016-11-21 B Purchase Clayman Michael D.

President and CEO

Executive Director
1,666 +6.5%
17.90
US$29,827 		1,666 +6.5% 17.90 US$29,827
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
400 +1.6%
13.71
US$5,483 		400 +1.6% 13.71 US$5,483
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
504 +2.0%
13.65
US$6,881 		504 +2.0% 13.65 US$6,881
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
4,600 +23.0%
13.76
US$63,288 		4,600 +23.0% 13.76 US$63,288
2016-06-22 2016-06-21 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
13,222 +195.1%
13.62
US$180,114 		13,222 +195.1% 13.62 US$180,114
2016-06-22 2016-06-20 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
3,343 +97.3%
13.70
US$45,813 		3,343 +97.3% 13.70 US$45,813
2016-06-22 2016-06-20 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
3,435 +inf%
13.98
US$48,020 		3,435 +inf% 13.98 US$48,020
2016-06-16 2016-06-14 B Purchase MERRIFIELD C ANN Non-Executive Director
1,000 +100.0%
13.39
US$13,387 		1,000 +100.0% 13.39 US$13,387
2016-06-10 2016-06-08 B Purchase LUBASH BARBARA N Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase COLELLA SAMUEL D Non-Executive Director Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase Versant Ventures III, LLC Large shareholder
4,194 +25.3%
14.00
US$58,716 		4,194 +25.3% 14.00 US$58,716
2016-06-10 2016-06-08 B Purchase LUBASH BARBARA N Large shareholder
710,091 +25.3%
14.00
US$9,941,274 		710,091 +25.3% 14.00 US$9,941,274
Explore more

More insider trading research around Flexion Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America